NewEdge Advisors LLC Has $28.81 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

NewEdge Advisors LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.0% during the 4th quarter, Holdings Channel reports. The firm owned 334,968 shares of the company’s stock after buying an additional 12,813 shares during the period. NewEdge Advisors LLC’s holdings in Novo Nordisk A/S were worth $28,814,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Insigneo Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S by 3.4% in the 4th quarter. Insigneo Advisory Services LLC now owns 12,359 shares of the company’s stock valued at $1,063,000 after purchasing an additional 412 shares during the period. NFJ Investment Group LLC increased its position in Novo Nordisk A/S by 89.1% during the fourth quarter. NFJ Investment Group LLC now owns 10,143 shares of the company’s stock worth $873,000 after buying an additional 4,779 shares during the last quarter. Evergreen Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 7.3% in the fourth quarter. Evergreen Capital Management LLC now owns 31,705 shares of the company’s stock valued at $2,727,000 after buying an additional 2,148 shares during the last quarter. Kane Investment Management Inc. bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $781,000. Finally, Lafayette Investments Inc. increased its holdings in shares of Novo Nordisk A/S by 48.7% during the 4th quarter. Lafayette Investments Inc. now owns 5,946 shares of the company’s stock worth $511,000 after acquiring an additional 1,946 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $62.88 on Thursday. Novo Nordisk A/S has a 12-month low of $59.32 and a 12-month high of $148.15. The firm has a 50-day moving average price of $76.55 and a two-hundred day moving average price of $92.55. The company has a market capitalization of $282.18 billion, a P/E ratio of 19.11, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.54%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday. They set an “underperform” rating for the company. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.